Trials / Terminated
TerminatedNCT00958841
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pasireotide LAR | Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2009-08-13
- Last updated
- 2016-07-26
- Results posted
- 2016-07-26
Locations
42 sites across 12 countries: United States, Argentina, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Russia, Spain, Thailand
Source: ClinicalTrials.gov record NCT00958841. Inclusion in this directory is not an endorsement.